{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:56:14Z","timestamp":1794916574368,"version":"4.9.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ijantimicag.2020.106076","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T12:01:46Z","timestamp":1593777706000},"page":"106076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antibiotic route and duration of therapy for cellulitis: data extracted from a multi-center clinical trial"],"prefix":"10.1016","volume":"56","author":[{"given":"O. Martin","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Brindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106076_bib0001","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jinf.2016.06.002","article-title":"Audit of guidelines for antimicrobial management of cellulitis across English NHS hospitals reveals wide variation","volume":"73","author":"Williams","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0002","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1468-3083.2004.00938.x","article-title":"Intramuscular bipenicillin vs.. Intravenous penicillin in the treatment of erysipelas in adults: Randomized controlled study","volume":"18","author":"Zeglaoui","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0003","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/jac\/dku397","article-title":"Oral versus parenteral antimicrobials for the treatment of cellulitis: A randomized non-inferiority trial","volume":"70","author":"Aboltins","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0004","article-title":"Interventions for cellulitis and erysipelas","author":"Kilburn","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0005","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamadermatol.2019.0884","article-title":"Assessment of antibiotic treatment of cellulitis and erysipelas: A systematic review and meta-analysis","volume":"155","author":"Brindle","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013260","article-title":"Adjunctive clindamycin for cellulitis: A clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis","volume":"7","author":"Brindle","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0007","series-title":"Guidelines on the management of cellulitis in adults","year":"2005"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0008","series-title":"Cellulitis and erysipelas: Antimicrobial prescribing. National Institue of Health and Care Excellence guideline 141","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0009","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00003246-199206000-00025","article-title":"American College of Chest Physicians\/Society of Critical Care Medicine consensus conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"20","year":"1992","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0010","series-title":"Clinical evidence","first-page":"1146","article-title":"Cellulitis and erysipelas","author":"Morris","year":"2001"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0011","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.medmal.2016.04.005","article-title":"Management of non-necrotizing cellulitis in france","volume":"46","author":"Lemaire","year":"2016","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0012","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00228-012-1240-7","article-title":"Variability of antimicrobial prescribing in patients with acute cellulitis","volume":"68","author":"Davies","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0013","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/MEJ.0000000000000245","article-title":"The management of cellulitis in emergency departments: Antibiotic-prescribing practices and adherence to practice guidelines in ireland","volume":"23","author":"Quirke","year":"2016","journal-title":"Eur J Emerg Med"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0014","doi-asserted-by":"crossref","first-page":"160","DOI":"10.7861\/clinmedicine.18-2-160","article-title":"Diagnosis and management of cellulitis","volume":"18","author":"Sullivan","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2133.1992.tb08048.x","article-title":"Roxithromycin versus penicillin in the treatment of erysipelas in adults: A comparative study","volume":"127","author":"Bernard","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0016","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bmj.325.7369.864","article-title":"Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: Randomised, non-inferiority, open trial","volume":"325","author":"Bernard","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0017","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/cid\/cit122","article-title":"Clinical trial: Comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: A randomized controlled trial","volume":"56","author":"Pallin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0018","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01645222","article-title":"The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas","volume":"12","author":"Jorup-Ronstrom","year":"1984","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0019","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/cid\/ciw463","article-title":"Early response in cellulitis: A prospective study of dynamics and predictors","volume":"63","author":"Bruun","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0020","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/archinte.164.15.1669","article-title":"Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis","volume":"164","author":"Hepburn","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0021","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0022","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/030006059101900602","article-title":"erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European azithromycin study group","volume":"19","author":"Azithromycin","year":"1991","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0023","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0024","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cmi.2019.09.019","article-title":"Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: A multicentre randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"26","author":"Cranendonk","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1053\/ajem.2001.28330","article-title":"ED management of cellulitis: A review of five urban centers","volume":"19","author":"Dong","year":"2001","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ijantimicag.2020.106076_bib0026","article-title":"Over-admission and over-treatment of patients with cellulitis: A 5-year audit against international guidelines","author":"Kiely","year":"2019","journal-title":"Ir J Med Sci"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:38:31Z","timestamp":1760377111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920302466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0924857920302466"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106076","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic route and duration of therapy for cellulitis: data extracted from a multi-center clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106076"}}